Table 1

Baseline characteristics and demographics of patients

VariableDulaglutide 1.5 mg
(n = 279)Dulaglutide 0.75 mg
(n = 280)Exenatide
(n = 276)Placebo
(n = 141)
Sex
 Male163 (58)168 (60)156 (57)83 (59)
 Female116 (42)112 (40)120 (44)58 (41)
Age (years)56 ± 1056 ± 955 ± 1055 ± 10
Race
 Hispanic or Latino93 (33)102 (36)91 (33)45 (32)
 Not Hispanic or Latino186 (67)178 (64)184 (67)96 (68)
 American Indian40 (14)37 (13)38 (14)20 (14)
 Asian6 (2)8 (3)4 (1)6 (4)
 Black24 (9)24 (9)18 (7)10 (7)
 Multiple3 (1)3 (1)3 (1)2 (1)
 Native Hawaiian1 (<1)1 (<1)1 (<1)0 (0)
 White205 (74)207 (74)211 (76)103 (73)
BMI (kg/m2)33 ± 533 ± 634 ± 533 ± 6
Weight96 ± 2096 ± 2197 ± 1994 ± 19
Diabetes duration (years)9 ± 69 ± 59 ± 69 ± 6
HbA1c (%)8.1 ± 1.38.1 ± 1.28.1 ± 1.38.1 ± 1.3
HbA1c (mmol/mol)65 ± 1465 ± 1365 ± 1465 ± 14
FPG (mg/dL)162 ± 56159 ± 50164 ± 55166 ± 54
OAM treatmenta
 1 OAM55 (20)67 (24)76 (27)44 (31)
 2 OAMs155 (56)142 (51)135 (49)62 (44)
 >2 OAMs63 (23)67 (24)66 (24)33 (23)
SBP (mmHg)127 ± 15127 ± 15127 ± 15125 ± 14
DBP (mmHg)81 ± 977 ± 1077 ± 1077 ± 11
  • Data are mean ± SD or n (%) unless otherwise indicated. DBP, diastolic blood pressure; SBP, systolic blood pressure.

  • aAt screening.